Citicholine
Lacunar Anterior Circulation Infarct
Dexa Medica GroupPhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Lacunar Anterior Circulation Infarct cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
SIMVASTATIN Dexa Medica Group | Phase 2/3 | B |
Dlbs1033 Dexa Medica Group | Phase 2/3 | CC |
Same molecule, other indications
Citicholine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →